ArticleFrontiers in cardiovascular medicine2026
Long-term follow-up evaluation of readmissions after ventricular assist device implantation: trends and outcomes.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With the increasing utilization of left ventricular assist devices (LVADs) as a pivotal treatment option for end-stage heart failure, the rehospitalization of patients equipped with these devices has emerged as a significant issue impacting both quality of life and healthcare costs. This study evaluates readmission trends, predisposing factors, and their effects on survival over a long-term follow-up period for patients undergoing LVAD implantation. Methods: The study included 141 patients who underwent LVAD implantation between 2015 and 2023 and were followed for a minimum of 12 months. We analyzed the reasons for readmission, trends related to the devices, and overall outcomes. Results: The median duration of LVAD support was 49 months (IQR: 22-60). Overall, 102 patients (72.3%) experienced at least one readmission, with a median of two readmissions per patient (IQR: 0-3). Patients who were readmitted had a significantly higher body mass index (median 26.3 kg/m Conclusion: Although LVAD implantation substantially improves survival in advanced heart failure, hospital readmissions remain common throughout long-term follow-up. Right ventricular dysfunction represents a key determinant of readmission risk, highlighting the importance of optimized perioperative management and vigilant monitoring for right-sided failure. Preventive strategies aimed at early detection of RV dysfunction and driveline complications may further reduce rehospitalizations and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.